Venetoclax

Generic Name
Venetoclax
Brand Names
Venclexta, Venclyxto
Drug Type
Small Molecule
Chemical Formula
C45H50ClN7O7S
CAS Number
1257044-40-8
Unique Ingredient Identifier
N54AIC43PW
Background

Venetoclax is a BCL-2 inhibitor that was initially approved by the FDA in April 2016 . Proteins in the B cell CLL/lymphoma 2 (BCL-2) family are important regulators of the apoptotic (programmed cell death) process , . Venetoclax is used to treat chronic lymphocytic leukemia (CLL) and certain types of small lymphocytic lymphoma . CLL is the most prevalent leukemia diagnosed in Western countries . Venetoclax was developed through reverse engineering of the BCL-2 protein family inhibitor, navitoclax . Venetoclax is approximately 10 times more potent than navitoclax with regard to induction of apoptosis in CLL cells . A new indication was approved in 2018 for the treatment patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), with or without 17p deletion, who have received at least one prior therapy . Previously, this drug was indicated only for patients with 17p gene deletion .

Indication

本品与阿扎胞苷联合用于治疗因合并症不适合接受强诱导化疗,或者年龄75岁及以上的新诊断的成人急性髓系白血病患者。

Associated Conditions
Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Associated Therapies
-

A Phase I-II Study Investigating the All Oral Combination of the Menin Inhibitor SNDX-5613 With Decitabine/Cedazuridine (ASTX727) and Venetoclax in Acute Myeloid Leukemia (SAVE)

First Posted Date
2022-05-04
Last Posted Date
2024-10-30
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
43
Registration Number
NCT05360160
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Acalabrutinib in Combination With Venetoclax or Obinutuzumab for the Treatment of Treatment-naive Chronic Lymphocytic Leukemia

First Posted Date
2022-04-20
Last Posted Date
2024-03-15
Lead Sponsor
Ohio State University Comprehensive Cancer Center
Target Recruit Count
52
Registration Number
NCT05336812
Locations
🇺🇸

Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States

Pirtobrutinib (LOXO-305) Consolidation for MRD Eradication in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL) Treated With Venetoclax

First Posted Date
2022-04-08
Last Posted Date
2024-10-14
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
44
Registration Number
NCT05317936
Locations
🇺🇸

M D Anderson Cancer Center, Houston, Texas, United States

Venetoclax to Augment Epigenetic Modification and Chemotherapy

First Posted Date
2022-04-07
Last Posted Date
2024-11-26
Lead Sponsor
Medical College of Wisconsin
Target Recruit Count
40
Registration Number
NCT05317403
Locations
🇺🇸

Children's Wisconsin, Milwaukee, Wisconsin, United States

Real World Outcomes Using Novel Agents for AML in the UK

First Posted Date
2022-04-05
Last Posted Date
2023-03-02
Lead Sponsor
Guy's and St Thomas' NHS Foundation Trust
Target Recruit Count
1000
Registration Number
NCT05312112
Locations
🇬🇧

Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom

CC-486 and Venetoclax for Acute Myeloid Leukemia

Phase 1
Recruiting
Conditions
Interventions
First Posted Date
2022-03-18
Last Posted Date
2024-05-16
Lead Sponsor
University of Colorado, Denver
Target Recruit Count
22
Registration Number
NCT05287568
Locations
🇺🇸

CU Anschutz Medical Campus, Aurora, Colorado, United States

🇺🇸

University of Colorado Hospital, Aurora, Colorado, United States

A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneous (SC) Epcoritamab in Combination With Oral and Intravenous Anti-Neoplastic Agents in Adult Participants With Non-Hodgkin Lymphoma

First Posted Date
2022-03-17
Last Posted Date
2024-12-03
Lead Sponsor
Genmab
Target Recruit Count
394
Registration Number
NCT05283720
Locations
🇺🇸

Alliance for Multispecialty Research (AMR) - Kansas City /ID# 242144, Kansas City, Missouri, United States

🇺🇸

Northwell Health - Monter Cancer Center /ID# 245435, Lake Success, New York, United States

🇺🇸

Icahn School of Medicine at Mount Sinai /ID# 242123, New York, New York, United States

and more 71 locations

A Phase II Study of the Combination of Ponatinib With Mini-hyper CVD Chemotherapy and Venetoclax in Patients With Relapsed or Refractory T-cell Acute Lymphoblastic Leukemia

First Posted Date
2022-03-07
Last Posted Date
2024-10-22
Lead Sponsor
M.D. Anderson Cancer Center
Target Recruit Count
26
Registration Number
NCT05268003
Locations
🇺🇸

MD Anderson Cancer Center, Houston, Texas, United States

© Copyright 2024. All Rights Reserved by MedPath